Lundbeck Completes Patient Enrollment in Phase III DEEp OCEAN Trial for Rare Epilepsy Treatment
Event summary
- Lundbeck has randomized the last patient in its Phase III DEEp OCEAN trial evaluating bexicaserin for developmental and epileptic encephalopathies (DEEs).
- The trial enrolled over 350 participants aged 2 to 65 years across more than 60 genetic DEE subtypes.
- Headline results are expected by the end of Q4 2026 or Q1 2027.
- Bexicaserin has received Breakthrough Therapy Designation in the U.S. and China for treating seizures associated with DEEs.
The big picture
Lundbeck's completion of the DEEp OCEAN trial marks a significant step in addressing the unmet needs of patients with developmental and epileptic encephalopathies. The trial's broad inclusion criteria reflect the heterogeneity of these rare conditions, positioning bexicaserin as a potential best-in-class treatment if Phase III results are positive. Success could expand Lundbeck's footprint in neuroscience, particularly in the neuro-rare disease space.
What we're watching
- Regulatory Pathway
- Whether the Breakthrough Therapy Designation will accelerate U.S. and Chinese approval processes for bexicaserin.
- Clinical Efficacy
- The extent to which bexicaserin demonstrates superior efficacy across diverse DEE subtypes in Phase III results.
- Market Positioning
- How Lundbeck positions bexicaserin against existing treatments for DEEs, given the lack of approved therapies spanning all subtypes.